2024/03/12 更新

写真a

オオイエ ユミ
大家 祐実
OIE Yumi
所属
医学部附属病院 放射線科 病院助教
職名
病院助教
 

論文 3

  1. Optimized radiotherapy treatment strategy for early glottic carcinoma 査読有り

    Ono, T; Itoh, Y; Ishihara, S; Kawamura, M; Oie, Y; Takase, Y; Okumura, M; Oyoshi, H; Nagai, N; Naganawa, S

    NAGOYA JOURNAL OF MEDICAL SCIENCE   85 巻 ( 2 ) 頁: 241 - 254   2023年5月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    The local control rates of T1 bulky and T2 glottic carcinoma treated via radiation therapy alone are unsatisfactory; thus, we aimed to evaluate the efficacy and safety of our treatment protocol for early glottic carcinoma. Patients with early glottic squamous cell carcinoma treated via radiation therapy from January 2007 to November 2019 were reviewed. Patients were treated with: 63–67.5 Gy/28–30 fractions of radiation therapy alone for T1 non-bulky; concurrent chemoradiotherapy with S-1 and 60 Gy/30 fractions for T1 bulky and T2 favorable; and concurrent chemoradiotherapy with high-dose cisplatin and 66–70 Gy/33–35 fractions for T2 unfavorable glottic carcinoma. Local failure rates were estimated using the cumulative incidence function, overall and disease specific survival rates were estimated using Kaplan-Meier analysis, and adverse events were evaluated. Eighty patients were analyzed; the median age was 69.5 (range, 26–90) years, the median follow-up time for survivors was 40.1 (range, 1.9–128.4) months, and the 3-year local failure, disease specific survival, and overall survival rates were 5.8%, 98.3%, and 94.4%, respectively. In T1 bulky and T2 cases, the local failure rate was significantly lower in the concurrent chemoradiotherapy than in the radiation therapy alone group. Grade 3 acute dermatitis and mucositis were noted in nine and four patients, respectively. There were no acute adverse events of Grade 4 or higher, or late adverse events of Grade 2 or higher. The treatment protocol was effective and well-tolerated; thus, the efficacy of concurrent chemoradiotherapy was suggested in T1 bulky and T2 cases

    DOI: 10.18999/nagjms.85.2.241

    Web of Science

    Scopus

    PubMed

  2. retrospective study of cervical cancer with radiation dose reduction in concurrent chemoradiotherapy

    Nagai, N; Kawamura, M; Ishihara, S; Oie, Y; Kozai, Y; Takase, Y; Okumura, M; Shindo, Y; Yasui, R; Yanagi, Y; Naganawa, S

    RADIOTHERAPY AND ONCOLOGY   182 巻   頁: S1921 - S1922   2023年5月

     詳細を見る

  3. Stereotactic radiotherapy for ventricular tachycardia: A study protocol 査読有り

    Kawamura M., Shimojo M., Inden Y., Kamomae T., Okudaira K., Komada T., Aoki S., Shindo Y., Yasui R., Yanagi Y., Okumura M., Yamada T., Kozai Y., Oie Y., Kato Y., Ishihara S., Murohara T., Naganawa S.

    F1000Research   12 巻   頁: 798   2023年

     詳細を見る

    記述言語:英語   出版者・発行元:F1000Research  

    Background: Currently, the standard curative treatment for ventricular tachycardia (VT) and ventricular fibrillation (VF) is radiofrequency catheter ablation. However, when the VT circuit is deep in the myocardium, the catheter may not be delivered, and a new, minimally invasive treatment using different energies is desired. Methods: This is a protocol paper for a feasibility study designed to provide stereotactic radiotherapy for refractory VT not cured by catheter ablation after at least one catheter ablation. The primary end point is to evaluate the short-term safety of this treatment and the secondary endpoint is to evaluate its efficacy as assessed by the reduction in VT episode. Cyberknife M6 radiosurgery system will be used for treatment, and the prescribed dose to the target will be 25Gy in one fraction. The study will be conducted on three patients. Conclusion: Since catheter ablation is the only treatment option for VT that is covered by insurance in Japan, there is currently no other treatment for VT/VF that cannot be cured by catheter ablation. We hope that this feasibility study will provide hope for patients who are currently under the stress of ICD activation. Trial registration: The study has been registered in the Japan Registry of Clinical Trials (jRCTs042230030).

    DOI: 10.12688/f1000research.138758.2

    Scopus

    PubMed